300595 Stock Overview
Autek China Inc. provides eye health and myopia prevention, and control technology and services in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Autek China Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.83 |
| 52 Week High | CN¥35.03 |
| 52 Week Low | CN¥15.20 |
| Beta | 0.60 |
| 1 Month Change | 1.02% |
| 3 Month Change | 13.50% |
| 1 Year Change | -41.47% |
| 3 Year Change | -76.92% |
| 5 Year Change | 35.78% |
| Change since IPO | 89.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300595 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | 6.6% | 5.3% | 3.1% |
| 1Y | -41.5% | -13.9% | -13.1% |
Return vs Industry: 300595 underperformed the CN Medical Equipment industry which returned -13.9% over the past year.
Return vs Market: 300595 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 300595 volatility | |
|---|---|
| 300595 Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300595 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300595's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,229 | Yuequn Tao | www.orthok.cn |
Autek China Inc. provides eye health and myopia prevention, and control technology and services in China. It operates through Ophthalmology and Optometry Medical Equipment; and Ophthalmology Service segments. The company offers rigid contact lenses including orthokeratology lenses and supporting care products.
Autek China Inc. Fundamentals Summary
| 300595 fundamental statistics | |
|---|---|
| Market cap | CN¥16.89b |
| Earnings (TTM) | CN¥686.34m |
| Revenue (TTM) | CN¥1.80b |
24.6x
P/E Ratio9.4x
P/S RatioIs 300595 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300595 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.80b |
| Cost of Revenue | CN¥464.74m |
| Gross Profit | CN¥1.34b |
| Other Expenses | CN¥649.15m |
| Earnings | CN¥686.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 74.18% |
| Net Profit Margin | 38.13% |
| Debt/Equity Ratio | 0.2% |
How did 300595 perform over the long term?
See historical performance and comparison